- Defence Therapeutics (DTC) is pleased to provide an update on its COVID-19 vaccine program with its first lead candidate AccuVAC-PT001
- Defence’s ACCUMTM platform enables precision delivery of vaccine antigens or ADCs in their intact form to target cells
- AccuVAC-PT001 is currently being tested on larger non-rodent animals to validate its potency and immunogenicity
- Defence Therapeutics Inc. is a biotechnology company focused on enhancing the delivery of tumour and infectious disease-specific therapeutics
- Defence Therapeutics Inc. (DTC) opened trading at C$4.87 per share
Defence Therapeutics (DTC) is pleased to provide an update on its COVID-19 vaccine program with its first lead candidate AccuVAC-PT001.
Defence’s ACCUMTM platform opens a new biotherapeutic modality by ensuring effective and distinct protein (antigen) processing by specialized antigen-presenting cells (dendritic cells) resulting in enhanced immune responses.
This is exemplified by the long-lasting and potent immune response induced with its AccuVAC-PT001 protein-based vaccine candidate against the SARS-CoV-2 Wuhan strain (additional studies targeting other COVID variants are underway).
These observations clearly highlight how the ACCUMTM platform can be applied to any infectious disease antigen as a means to dramatically boost its processing by dendritic cells and effectively stimulate immunity.
When tested in immunocompetent mice at an academic laboratory, Defence’s AccuVAC-PT001 generated a response lasting more than 18 weeks post-vaccination (the research study is expected to be released in Q4 of 2021). This is a breakthrough as most humoral responses induced by current vaccinations start waning in less than 8 weeks.
Additional studies completed at a private clinical research organization confirmed the blocking of infection by the virus when subjected to AccuVAC-PT001-induced antibodies.
“Defence’s focus is to advance our pipeline as we continuously progress towards clinical validation. Defence’s ability to leverage its distinct platform, ACCUMTM, creates both novel and potentially unprecedented therapeutics response targeting multiple illnesses,” says Sébastien Plouffe, Defence’s Chief Executive Officer.
In addition to completing standard toxicology studies to ensure the safety of the vaccine, AccuVAC-PT001 is currently being tested on larger non-rodent animals to validate its potency and immunogenicity.
“I am pleased with the continued progress and development of our pipeline. The potential of our ACCUMTM technology positions Defence to deliver solutions for current or future infectious diseases,” adds Mr. Plouffe.
Defence Therapeutics Inc. is a biotechnology company focused on enhancing the delivery of tumour and infectious disease-specific therapeutics. Defence Therapeutics platform ACCUM, enables precision delivery of vaccine antigens or ADCs in their intact form to target cells.
Defence Therapeutics Inc. (DTC) opened trading at C$4.87 per share.
